MART-1(1-20)

MART-1(1-20) is a synthetic peptide corresponding to the amino-terminal residues 1 through 20 of the Melanoma Antigen Recognized by T cells 1 (MART-1), also known as Melan-A. As a well-characterized segment of a tumor-associated antigen, this peptide plays a pivotal role in immunology, cancer research, and T cell epitope mapping. Its defined sequence and immunogenic properties make it a valuable reagent for dissecting antigen-specific immune responses, particularly in the context of melanoma biology. Researchers utilize this peptide to investigate the molecular basis of antigen recognition, T cell activation, and the development of immune-based assays and models.

Epitope mapping: MART-1(1-20) is extensively employed in studies aimed at identifying and characterizing T cell epitopes recognized by cytotoxic T lymphocytes (CTLs) and helper T cells. By providing a defined peptide sequence derived from a melanoma-associated antigen, it enables precise mapping of immunodominant regions involved in antigen presentation via major histocompatibility complex (MHC) molecules. This application is fundamental for understanding which peptide fragments are most relevant to immune surveillance and tumor recognition, supporting the rational design of immunological assays and research into antigen processing.

T cell functional assays: The peptide serves as a critical tool in the development and optimization of T cell activation assays, including ELISPOT, intracellular cytokine staining, and proliferation assays. By pulsing antigen-presenting cells or peripheral blood mononuclear cells (PBMCs) with MART-1(1-20), researchers can evaluate the frequency, specificity, and functional activity of T cells reactive to melanoma antigens. Such applications are instrumental in assessing immune competence, monitoring responses in preclinical models, and validating immunotherapeutic strategies targeting tumor antigens.

Immunogenicity assessment: Investigators leverage MART-1(1-20) to assess the immunogenic potential of peptide epitopes in vitro. The peptide's well-defined sequence allows for controlled studies of antigen processing and presentation, providing insights into the determinants of T cell recognition and the factors influencing peptide-MHC binding affinity. These studies inform the selection of candidate epitopes for further research and facilitate the evaluation of immune responses in various experimental settings.

Peptide-MHC binding studies: The defined structure of MART-1(1-20) makes it suitable for in vitro binding assays with purified MHC molecules or MHC-expressing cells. By quantifying binding affinities and stability, researchers can elucidate the structural and biochemical determinants governing peptide presentation. Such investigations are essential for understanding how antigenic peptides are selected and displayed by MHC molecules, which has direct implications for the design of peptide-based vaccines and immunotherapies.

Antigen processing research: The peptide is also valuable in studies focused on elucidating the intracellular mechanisms of antigen processing and presentation. By tracing the fate of exogenously supplied MART-1(1-20) in cellular systems, scientists can dissect the pathways involved in peptide uptake, degradation, and loading onto MHC molecules. This application provides critical insights into the efficiency and specificity of antigen presentation, advancing the broader understanding of immune recognition in the context of tumor immunology and adaptive immunity.

1. Identification, Localization in the Central Nervous System and Novel Myostimulatory Effect of Allatostatins in Tenebrio molitor Beetle

2. Peptides as Active Ingredients: A Challenge for Cosmeceutical Industry

3. Uncarboxylated osteocalcin decreases insulin-stimulated glucose uptake without affecting insulin signaling and regulators of mitochondrial biogenesis in myotubes

4. Odorant binding protein based biomimetic sensors for detection of alcohols associated with Salmonella contamination in packaged beef

5. High fat diet and GLP-1 drugs induce pancreatic injury in mice